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Abstract
Background: Epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) formation are key underlying
causes that promote extensive metastasis, drug resistance, and tumor recurrence in highly lethal pancreatic cancer.
The mechanisms leading to EMT and CSC phenotypes are not fully understood, which has hindered the development
of effective targeted therapies capable of improving treatment outcomes in patients with pancreatic cancer.
Results: We show a central role of Aurora kinase A (AURKA) in promoting EMT and CSC phenotypes via ALDH1A1,
which was discovered as its direct substrate using an innovative chemical genetic screen. AURKA phosphorylates
ALDH1A1 at three critical residues which exert a multifaceted regulation over its level, enzymatic activity, and
quaternary structure. While all three phosphorylation sites contribute to its increased stability, T267 phosphorylation
primarily regulates ALDH1A1 activity. AURKA-mediated phosphorylation rapidly dissociates tetrameric ALDH1A1 into a
highly active monomeric species. ALDH1A1 also reciprocates and prevents AURKA degradation, thereby triggering a
positive feedback activation loop which drives highly aggressive phenotypes in cancer. Phospho-resistant ALDH1A1
fully reverses EMT and CSC phenotypes, thus serving as dominant negative, which underscores the clinical significance
of the AURKA-ALDH1A1 signaling axis in pancreatic cancer.
Conclusions: While increased levels and activity of ALDH1A1 are hallmarks of CSCs, the underlying molecular mechanism
remains unclear. We show the first phosphorylation-dependent regulation of ALDH1A1, which increases its levels and
activity via AURKA. Recent global phospho-proteomic screens have revealed increased phosphorylation of ALDH1A1 at
the T267 site in human cancers and healthy liver tissues where ALDH1A1 is highly expressed and active, indicating that
this regulation is likely crucial both in normal and diseased states. This is also the first study to demonstrate
oligomer-dependent activity of ALDH1A1, signifying that targeting its oligomerization state may be an effective
therapeutic approach for counteracting its protective functions in cancer. Finally, while AURKA inhibition provides
a potent tool to reduce ALDH1A1 levels and activity, the reciprocal loop between them ensures that their concurrent
inhibition will be highly synergistic when inhibiting tumorigenesis, chemoresistance, and metastasis in highly aggressive
pancreatic cancer and beyond.
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Background
Pancreatic cancer is an exceptionally aggressive disease
with the majority of its victims dying within 1 year of
diagnosis [1]. Effective early detection and screening are
not available, and tumors are typically diagnosed after
metastasis. Systemic chemotherapy, radiation therapy, or
a combination of both therapies is used; however, patients
rapidly develop resistance, leading to a poor 5-year survival
rate of only 6%. Accumulating evidence suggests that the
acquisition of epithelial-to-mesenchymal transition (EMT)
and cancer stem cell (CSC) phenotypes in pancreatic
tumors is an important underlying cause for extensive
local tumor invasion, early metastasis, drug resistance,
and tumor recurrence [2]. However, the mechanisms lead-
ing to EMT and CSC phenotypes are not fully understood,
which has hindered the development of effective targeted
therapies and sensitive biomarkers to improve treatment
outcomes in patients with pancreatic cancer.
We focused on Aurora kinase A (AURKA), as it is
overexpressed in a vast majority of pancreatic tumors
[3–5]. AURKA depletion inhibits in vivo tumorigenicity,
enhances taxane chemosensitivity, and induces apoptosis
in pancreatic cancer cells [6]. Data such as these have
resulted in ongoing clinical trials of more than a dozen
AURKA inhibitors. Despite these encouraging findings,
AURKA remains an essential kinase required for mitosis
in all dividing cells. Consequently, its inhibition in Phase
II clinical trials has been associated with several adverse
side effects, suggesting that collateral inhibition of AURKA
in rapidly proliferating normal tissues is responsible for the
undesirable side effects [7]. These findings indicate that
selective therapies against oncogenic targets of AURKA
exploited in cancer may be a superior option for devel-
oping effective drugs and combating collateral toxicity.
To this end, we identified aldehyde dehydrogenase 1
(ALDH1A1) as a direct substrate of AURKA using an
innovative chemical genetic screen that we developed.
ALDH1A1 is a pancreatic CSC marker and is highly
enriched in a subpopulation of cells which are extremely
resistant to chemotherapy. Furthermore, ALDH1 is highly
enriched in surgical specimens from patients with pan-
creatic cancer who had undergone preoperative chemo-
radiation therapy compared to untreated patients [8].
However, ALDH1A1 levels have not been analyzed in
pancreatic cancer. As AURKA overexpression is also
associated with enhanced chemoresistance, we hypoth-
esized that AURKA may upregulate ALDH1A1 leading
to EMT, CSC phenotypes, and chemoresistance in pan-
creatic cancer.
Methods
Antibodies against AURKA (H-130), actin (C-2), tubulin
(TU-02), and ALDH1A1 (B-5) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) (for
RRIDs and/or lot numbers see Additional file 1). Cell cul-
ture BxPC3, Panc1, and HEK293T cells were purchased
from American Type Culture Collection (ATCC, Manassas,
VA, USA). Validated antibodies against Snail (40084), Slug
(40088), N-cadherin (39429), and CD44 (39435) were
purchased from One World Lab (San Diego, CA, USA)
and were used at 1:5000 dilution. Antibodies against
vimentin (bs-0756R), E-cadherin (bs-10009R), and matrix
metalloproteinase-2 (MMP-2) (bs-4599R) were purchased
from Bioss Antibodies and used at 1:1000 dilution
(Additional file 1). BxPC3 and Panc1 cells were cultured
in RPMI with 10% fetal bovine serum (FBS) supplemented
with 2 mM glutamine and antibiotics. HEK293T and
Phoenix cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% FBS supplemented with 2 mM
glutamine and antibiotics.
Expression plasmids and constructs
Human influenza hemagglutinin (HA)-tagged wild-type
and mutant ALDH1A1 were cloned into VIP3 mamma-
lian vector and bacterial petDuet vector at EcoRI and
XhoI sites. HA-tagged ALDH1A1 mutants were gener-
ated using site-directed mutagenesis.
Expression and purification of AURKA, TPX2, and
ALDH1A1
AURKA was prepared using the Baculovirus Bac-to-Bac
Expression System according to the manufacturer’s
instructions (Invitrogen). 6x-His-TPX2 and 6x-His-tagged
wild-type and mutant ALDH1A1 were expressed in
Escherichia coli and purified using the procedures pre-
viously described [9, 10].
Transfection and retroviral infection
For generating stable cell lines, AURKA and ALDH1A1
plasmids were transiently transfected using calcium phos-
phate into Phoenix cells. The retroviruses were harvested
and used to infect BxPC3 cells as reported previously [11].
In vitro kinase assays
For in vitro labeling, AURKA-TPX2 complex (on Ni-NTA
beads) was pre-incubated with 100 μM of ATP for 1 h in a
1× kinase buffer (50 mM Tris, 10 mM MgCl2) to activate
AURKA. The beads were washed extensively with 1×
kinase buffer to remove excess ATP, and then subjected
to an in vitro kinase assay with 2 μg of 6x-His-tagged
recombinant protein (wild-type or mutant ALDH1A1)
in the presence of 0.5 μCi of [γ-32P]ATP for 15 min.
Reactions were terminated upon the addition of sodium
dodecyl sulfate (SDS) loading buffer and subsequently
separated by SDS-PAGE gel, transferred to a polyvinyli-
dene difluoride (PVDF) membrane, and exposed for
autoradiography.
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AURKA and ALDH1A1 shRNA
AURKA short hairpin RNAs (shRNAs) were generated in
our previous study [12]. Both AURKA and ALDH1A1
shRNAs were cloned into the pLKO.1 TRC vector, which
was a gift from David Root [13]. The sequences are as
follows:
AURKA shRNA1 (forward): 5′-CCGG GGC TTT GGA
AGA CTT TGA AAT CTCGAG ATT TCA AAG TCT
TCC AAA GCC TTTTTG-3′. AURKA shRNA1 (reverse):
5′- AATTCAAAAA GGC TTT GGA AGA CTT TGA
AAT CTCGAG ATT TCA AAG TCT TCC AAA GCC-
3′. AURKA shRNA2 (forward): 5′- CCGG GCA CCA
CTT GGA ACA GTT TAT CTCGAG ATA AAC TGT
TCC AAG TGG TGC TTTTTG-3′. AURKA shRNA2
(reverse): 5′-AATTCAAAAA GCA CCA CTT GGA
ACA GTT TAT CTCGAG ATA AAC TGT TCC AAG
TGG TGC-3′. AURKA shRNA3 (forward): 5′-CCGG
GCC AAT GCT CAG AGA AGT ACT CTCGAG AGT
ACT TCT CTG AGC ATT GGC TTTTTG-3′. AURKA
shRNA3 (reverse): 5′-AATTCAAAAA GCC AAT GCT
CAG AGA AGT ACT CTCGAG AGT ACT TCT CTG
AGC ATT GGC-3′. ALDH1A1 shRNA1 (forward): 5′ C
CGG AGC CTT CAC AGG ATC AAC AGA CTC
GAG TCT GTT GAT CCT GTG AAG GCT TTT
TTG 3′. ALDH1A1 shRNA1 (reverse): 5′ A ATT CAA
AAA AGC CTT CAC AGG ATC AAC AGA CTC
GAG TCT GTT GAT CCT GTG AAG GCT 3′.
ALDH1A1 shRNA2 (forward): 5′ C CGG ACC TCA
TTG AGA GTG GGA AGA CTC GAG TCT GTT
GAT CCT GTG AAG GCT TTT TTG 3′. ALDH1A1
shRNA2 (reverse): 5′ A ATT CAA AAA ACC TCA
TTG AGA GTG GGA AGA CTC GAG TCT GTT
GAT CCT GTG AAG GCT 3′. Control shRNA (scrambled
shRNA), AURKA, and ALDH1A1 shRNA lentiviruses were
generated and used for infecting BxPC3 cells. Stable cells
were generated following puromycin selection.
Soft agar colony formation
BxPC3, Panc1, and different stable cell lines were plated
in RPMI (103, 104, and 105 cells per dish in triplicate),
0.3% agar, and 10% FBS six-well plates as reported
previously [11]. Transformed colonies were counted
after 3 weeks using crystal violet staining.
Western blotting
Cells were lysed in modified radioimmunoprecipitation
assay (RIPA) buffer, supplemented with protease inhibitors.
Equal amounts of cell extracts were used for western
blotting.
Ubiquitylation assay
BxPC3 cells were co-transfected with ALDH1A1 or
AURKA shRNA along with 6x-His-ubiquitin. After 36 h,
MG132 (Sigma) was added at 10 μM final concentration
for an additional 12 h. Cells were then harvested, and ubi-
quitylated proteins were isolated using Ni-NTA beads. The
proteins were separated by SDS-PAGE and analyzed using
antibodies against AURKA and ALDH1A1.
Chemotaxis assay
Cell migration was determined using Boyden chambers
as reported previously [14]. The assays were performed
in replicates of three, in four independent experiments.
To allow for comparison between multiple assays, the
data were normalized and expressed as a percentage of
the number of cells present on the membrane.
MTT assay
Cells were seeded in 96-well plates at 5 × 103 cells per
100 μL per well and cultured for 24, 48, and 72 h. The
MTT assay was conducted as reported previously [15].
Experiments were repeated three times in triplicate wells
to ensure reproducibility.
Immunofluorescence
BxPC3 and Panc1 cells were grown on poly-L-lysine-
coated coverslips for 24 h, fixed with 4% formaldehyde
in PBS for 15 min at room temperature, and then
washed three times with PBS. The cells were blocked in
1% FBS, 2% bovine serum albumin (BSA), 0.1% triton X-
100 in PBS for 1 h at 25 °C. Cells were labeled with anti-
bodies (Actin, AURKA, or ALDH1A1) for 3 h in PBS,
followed by incubation with fluorescein isothiocyanate- or
Texas Red-conjugated secondary antibody. Cells were
visualized using a Nikon Eclipse E600 microscope (Nikon
Instruments, Melville, NY, USA).
ALDH1A1 activity assay
The ALDH1A1 activity assay was conducted in 100 mM
Hepes buffer (pH 8.0) containing 2 mM DTT, 5 mM
NAD+, 1.5 mM MgCl2, and 37.5 mM imidazole. The
relative concentrations of wild-type and each mutant
were determined by SDS-PAGE densitometry to ensure
equal concentration in all samples. To measure the
consequences of AURKA-mediated phosphorylation
on ALDH1A1 activity, it was phosphorylated using
AURKA/TPX2 in kinase buffer (37.5 mM Hepes
pH 8.00, 300 μM ATP, 4 mM MgCl2). Each reaction was
then diluted with Hepes-BSA buffer so that each sample
contained 100 mM Hepes pH 8.00, 77.4 μM ATP,
1.03 mM MgCl2, 0.65% BSA, and 5 mM NAD
+. Reac-
tions were initiated upon the addition of propanal to a
final concentration of 4 mM. The change in absorbance
at 360 nm due to NADH formation was measured in a
96-well plate format (SpectraFluor PLUS, TECAN). The
data are shown as the fractional conversion of NAD+ to
NADH to highlight the relative intrinsic activity of
wild-type and mutants and effect of AURKA-dependent
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phosphorylation. For the dephosphorylation experiment,
ALDH1A1 activity was measured for 45 min, at which time
1 μL of calf-alkaline phosphatase was added to the sample
and the measurements were performed for another 1.5 h.
For untreated samples, 50% glycerol in 1x CutSmart Buffer
(New England Biolabs) was added as a control.
For experiments coupling the percentage of ALDH1A1
phosphorylation with a change in its dehydrogenase activity
(Fig. 3g–i), recombinant AURKA-TPX2 and ALDH1A1
(0.74 mg/mL) were reacted on a 10 μL scale in the indi-
cated combinations in 1x kinase assay buffer containing
0.5 mM ATP at 30 °C. An identical reaction mixture
for samples containing ATP was treated with a tracer
amount (~0.01 μCi) of [γ-32P] ATP. After incubation
for varying periods, the kinase reactions were termi-
nated by adding EDTA. For activity measurements,
each sample was simultaneously treated with freshly pre-
pared 5 mM NAD+ and the initial reaction absorbance
was recorded. Reactions were initiated upon the addition
of propanal to a final concentration of 5 mM. The reaction
progress curves were monitored at 360 nm every 10 min
for 7 h. The reaction progress curves were plotted as (At-
Ao/Ao) to reflect the relative amounts of NADH produced
over time. For measuring percent phosphate incorporated
into ALDH1A1 (Fig. 3g), the radioactive reactions were
terminated via trichloroacetic acid (TCA) precipitation,
washed two times with 200 μL of 90% acetone, and
counted. To determine the percent phosphate incor-
porated into ALDH1A1, the background signal from
AURKA in the absence of ALDH1A1 was subtracted from
that containing both ALDH1A1 and AURKA. As AURKA
phosphorylates ALDH1A1 at three sites, we calculated the
percentage mol phosphorylation of ALDH1A1 per mole of
the protein accordingly.
Native gel analysis of AURKA-mediated ALDH1A1
phospho-oligomeric regulation
AURKA was immunoprecipitated from BxPC3 cells, and
a kinase reaction was carried out in 50 mM Tris pH 8.00,
10 mM MgCl2, 50 mM NaCl, and 50 mM imidazole
containing ~0.3–0.6 mg/mL ALDH1A1. Notably, when
high concentrations of ALDH1A1 were used (>1 mg/mL),
the change from tetramer to monomer was less pro-
nounced. The kinase reaction was initiated upon the
addition of ATP to a final concentration of 1 mM. The
reaction was spun down, and 10 μL of the supernatant
was mixed with 5 μL of 3x native running buffer contain-
ing 10 mM EDTA for the first time point. The reaction
tube was then placed on a thermomixer (800 rpm) at
room temperature. 10 μL aliquots of the supernatant
were collected at each time point indicated. The samples
were separated using clear-native PAGE (CN-PAGE) with a
7.5% resolving gel (pH 8.9) and a 4.3% stacking gel
(pH 6.7). Following electrophoresis, the gel was soaked in
1x SDS-PAGE running buffer for 5 min to denature
complexes, followed by 1x transfer buffer containing
20% methanol to remove excess SDS. Proteins were
transferred to a PVDF membrane, and ALDH1A1 was
visualized using a monoclonal anti-6x-His antibody.
In-gel ALDH1A1 activity assay
AURKA kinase was immunoprecipitated from BxPC3
cells and reacted for 30 min with ALDH1A1 as previ-
ously described. ALDH1A1 in the absence of AURKA
was used as a control. Samples were separated using
CN-PAGE 1.5 mm gels. Following electrophoresis, the
gel was soaked 2x for 5 min in 100 mM Tris pH 8.8, and
for an additional 5 min in 50 mL of 100 mM Tris pH 8.8
containing 15 mg nitrotetrazolium blue chloride (NBT)
and 25 mg NAD+. Colorimetric detection of ALDH1A1
activity was carried out by incubating the gel in the same
buffer as above with the addition of 1 mg of 1-methoxy
phenazine methosulfate (PMS) and 5 mM benzaldehyde
in the dark at 37oC with agitation. Bands were clearly
visible after 5 min and were allowed to intensify over
45 min. The reaction was terminated by soaking the gel in
a 10% acetic acid solution. The enzymatic activity was
visualized as a purple band due to formazan precipitation
upon NAD+ consumption. The gel was then fixed in
10% acetic acid and 40% methanol and stained with
Coomassie G-250.
Oligomer-specific phosphorylation of ALDH1A1
AURKA kinase was reacted with ALDH1A1 as previ-
ously described for 0, 10, and 30 min. Following CN-
PAGE, the gels were fixed in 10% acetic acid and 30%
methanol for 20 min and washed 3 times for 5 min
with water. Phos-tag staining was carried out accord-
ing to the manufacturer’s protocol. Gels were imaged
using a Typhoon© scanner equipped with a Phos-tag
filter. Following fluorescent detection, total protein
levels were visualized with Coomassie G-250 staining.
Protein quantification was determined by SDS-PAGE
densitometry. The Phos-tag gel was colorized using
ImageJ to denote it as a phosphorylation-specific
signal.
Luciferase assay
BxPC3 cells were plated in a 96-well plate at a density of
3000 cells/well. After 12 h, the cells were transfected
with 50 ng/well of Snail, Slug, CD44, or E-cadherin
promoter-driven luciferase plasmids using lipofectamine
(Invitrogen). Cells were simultaneously co-transfected
with 50 ng/well of the pRL-SV40 Renilla luciferase plas-
mid (Promega) as an internal control. After 48 h, firefly
and Renilla luciferase activities were measured with the
Dual Luciferase kit (Thermo Fisher Scientific). The firefly
luciferase signal was normalized to the Renilla luciferase
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signal to account for variations in transfection efficiency.
All experiments were performed in triplicate, three inde-
pendent times.
Statistical analysis
Bar graph results are plotted as the average ± standard
error of the mean (SEM). Significance was evaluated
using a two-tailed Student’s t test and two-way analysis
of variance and is displayed as follows: *p < 0.05, **p <
0.01, ***p < 0.001.
Results
ALDH1A1 is a direct target of AURKA
The chemical genetic approach involves an engineered
kinase, which in the presence of a radioactive orthogonal
ATP analog (e.g., N6-(benzyl) ATP, N6-(phenethyl) ATP),
specifically transfers the radioactive tag (32P) to its sub-
strates. The modified pocket in the engineered kinase is
created by replacing a conserved bulky residue in the
active site with glycine. The complementary substituent
on ATP is created by attaching bulky groups at the N-6
position of ATP. These ATP analogs are not accepted by
wild-type kinases, permitting unbiased identification of
direct substrates of the engineered kinase in a global en-
vironment [9–12, 14, 16–22]. Using the aforementioned
design criteria, we generated an AURKA mutant (called
AURKA-as7) that efficiently accepted N(6)phenethyl-ATP
(PE-ATP) as the orthogonal ATP analog. Using AURKA-
as7 and [32P] PE-ATP, we previously identified several novel
AURKA substrates including PHLDA1 and LIMK2
[12, 20]. In this study, we focused on ALDH1A1 as the
direct target of AURKA. To confirm the results obtained
from the chemical genetic screen, we conducted an in vitro
kinase assay using recombinant ALDH1A1 and AURKA,
which revealed that AURKA directly phosphorylates
ALDH1A1 (Fig. 1a).
AURKA regulates the subcellular localization of ALDH1A1
in pancreatic cancer cells
We next examined the subcellular localization of AURKA
and ALDH1A1 in BxPC3 and Panc1 cells. ALDH1A1
displayed cytoplasmic localization, which is consistent
with previous findings showing it to be a cytoplasmic
enzyme (Fig. 1b and c). AURKA too displayed cytoplas-
mic localization in both BxPC3 and Panc1 cells (Fig. 1d and
e). More importantly, when AURKA levels were knocked
down using AURKA-shRNA or inhibited using MLN8237
(aka alisertib, an AURKA-specific inhibitor), ALDH1A1
adopted somewhat perinuclear localization (compare actin
staining versus ALDH1A1 staining), suggesting that
AURKA regulates the subcellular localization of ALD-
HI1A1 to some extent in BxPC3 cells (Fig. 1f and h).
As shown in Fig. 1g and i, ~35% and 22% of BxPC3
cells displayed perinuclear localization of ALDH1A1 in
AURKA shRNA-treated and MLN8237-treated cells, re-
spectively. To examine whether AURKA-mediated regula-
tion of ALDH1A1 was common in other pancreatic cancer
cells, we investigated ALDH1A1 subcellular localization in
Panc1 cells in the absence or presence of either AURKA
shRNA or MLN8237. Similar to the results obtained in
BxPC3 cells, AURKA depletion or inhibition resulted in
moderate perinuclear localization of ALDH1A1 (Fig. 1j–m).
Data used to generate the summary statistics shown in
Fig. 1g, i, k, and m are reported in Additional file 2.
AURKA and ALDH1A1 associate in pancreatic cancer cells
To investigate whether AURKA associates with ALDH1A1
in BxPC3 cells, we isolated ALDH1A1 immune complex,
which pulled down AURKA (Fig. 2a). This finding was
corroborated by isolating AURKA immune complex, which
too revealed significant association with ALDH1A1 (Fig. 2b).
Similarly, we observed robust association of AURKA and
ALDH1A1 in Panc1 cells (Fig. 2c and d). These results con-
firm that both AURKA and ALDH1A1 associate with each
other in pancreatic cancer cells.
AURKA positively regulates ALDH1A1 levels
Our previous studies revealed that AURKA-mediated
phosphorylation of PHLDA1 at S98 degrades it, whereas
AURKA-mediated phosphorylation of LIMK2 at S283,
T494, and T505 increases its protein stability [12, 20].
Thus, we examined whether AURKA affects the protein
levels of ALDH1A1. Ectopic overexpression of AURKA
increased the levels of ALDH1A1 (Fig. 2e), and its deple-
tion using corresponding shRNAs decreased it (Fig. 2f ),
suggesting that AURKA positively regulates ALDH1A1
levels. Figure 2g shows quantification of alterations in
ALDH1A1 levels upon AURKA knock-down from three
independent experiments. We also inhibited AURKA using
MLN8237, which too resulted in substantial decrease
in ALDH1A1 levels, suggesting that AURKA regulates
ALDH1A1 using its kinase activity (Fig. 2h). We ob-
served similar AURKA-mediated positive regulation of
ALDH1A1 in Panc1 cells, suggesting that it is a com-
mon mechanism in pancreatic cancer cells (Fig. 2i–n).
Data used to generate the summary statistics shown in
Fig. 2g, j, l, and n are reported in Additional file 3.
AURKA inhibits ALDH1A1 degradation
As AURKA directly phosphorylates ALDH1A1, we hypoth-
esized that AURKA might increase ALDH1A1 levels by
inhibiting its degradation via phosphorylation. Thus, we
examined the profile of ALDH1A1 degradation in BxPC3
and AURKA-overexpressing BxPC3 (AURKA-BxPC3) cells
using cycloheximide. As shown in Fig. 3a–c, AURKA over-
expression reduced ALDH1A1 degradation, suggesting that
it regulates the level of ALDH1A1 by inhibiting its degrad-
ation. This study also revealed that the half-life of








Fig. 1 (See legend on next page.)
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ALDH1A1 was less than 2 h in BXPC3 cells. ALDH1A1
degradation could be mediated by ubiquitin or non-
ubiquitin mechanisms. We transfected 6x-His-ubiquitin
into BxPC3 and AURKA-depleted-BxPC3 cells, and ana-
lyzed the ubiquitylation of ALDH1A1. Knock-down of
AURKA led to increased ubiquitylation of ALDH1A1
(Fig. 3d), thus confirming that AURKA stabilizes
ALDH1A1 levels by inhibiting its degradation by
ubiquitylation.
AURKA increases the enzymatic activity of ALDH1A1
Increased ALDH1A1 levels and activity are hallmarks of
cancer stem cells. Thus, we investigated whether AURKA
modulates the enzymatic activity of ALDH1A1. We
designed a two-step approach to phosphorylate ALDH1A1
and subsequently measure its dehydrogenase activity. Due
to the nature of the assay, we selected five controls to
account for any phosphorylation-independent change in
dehydrogenase activity. Upon phosphorylation by AURKA,
we observed a robust increase in ALDH1A1 activity relative
to the phosphorylated controls (Fig. 3e). During our initial
experiments, we observed an increase in activity when
ALDH1A1 was incubated with ATP alone; however, this
change was less than that observed when in the presence of
AURKA and ATP (Fig. 3e). We hypothesized that this
increase was likely due to phosphorylation by bacterial
kinases co-purified with ALDH1A1 and/or a direct
interaction with ATP itself. We thus carried out a high-
stringency purification of ALDH1A1 to eliminate potential
impurities, which resulted in a robust increase in ALDH1A1
activity only when AURKA was able to phosphorylate
ALDH1A1 (Fig. 3f).
We observed that the increase in ALDH1A1 activity in
these experiments is highly influenced by the activity of
AURKA. Accordingly, if the ratio of phosphorylated to
unphosphorylated ALDH1A1 was too low, the change in
activity could not be observed. Thus, we needed to address
the stoichiometry of phosphorylation and correlate it with
the observed increase in activity.
To answer this question, we measured the activity and
the percent mol phosphate incorporated per mole of
ALDH1A1 (Fig. 3g). As expected, there was virtually no
observable change in ALDH1A1 activity after 1.5 h (Fig. 3h).
This was not surprising, as the stoichiometry of phosphor-
ylation was a mere 3.1% (Fig. 3g). However, after a 6-h
kinase reaction, the stoichiometry of phosphorylation
reached 38%, which was accompanied by an observable
increase in ALDH1A1 activity (Fig. 3i). This increase
was prevalent in the first several hours of the ALDH1A1
activity, as seen in the projections of each plot after 2 h
(Fig. 3h, i, right panel).
As an additional approach to confirm that the increase
in ALDH1A1 activity was indeed due to direct phosphoryl-
ation by AURKA, we treated phosphorylated ALDH1A1
with calf-intestinal alkaline phosphatase (CIP) and moni-
tored the impact on dehydrogenase activity (Fig. 3j). As pre-
dicted, the addition of CIP caused a decrease in the overall
activity, supporting that the change in activity observed
following the kinase assay was the result of direct phos-
phorylation by AURKA. Combined, these findings serve
to validate that ALDH1A1 enzymatic activity is regu-
lated via phosphorylation.
ALDH1A1 also positively regulates AURKA levels,
triggering a feedback activation loop
Interestingly, several AURKA substrates are known to
regulate the levels or activity of AURKA in a feedback
mechanism. Thus, we examined whether ALDH1A1
exhibits a similar impact on AURKA levels. We over-
expressed ALDH1A1, which revealed a concomitant in-
crease in AURKA levels, suggesting that a positive feedback
activation loop exists between the two proteins (Fig. 4a).
This finding was confirmed by depleting ALDH1A1 using
two different ALDH1A1 shRNAs, which led to a robust
decrease in AURKA levels (Fig. 4b). Figure 4c shows
(See figure on previous page.)
Fig. 1 AURKA directly phosphorylates ALDH1A1 and regulates its subcellular localization. a ALDH1A1 is directly phosphorylated by AURKA. AURKA-TPX2
complex was subjected to kinase assay with either [32P]ATP (lane 1) or with 6x-His-ALDH1A1 and [32P]ATP (lane 2) for 15 min. Lane 3 shows
ALDH1A1 incubated with [32P]ATP. b, c Subcellular localization of ALDH1A1 in (b) BxPC3 and (c) Panc1 cells treated with scrambled or ALDH1A1 shRNA for
30 h. d AURKA localization in BxPC3 and (e) Panc1 cells treated with scrambled or AURKA shRNA for 30 h. f AURKA regulates ALDH1A1 subcellular
localization in BxPC3 cells. Unsynchronized cells were either treated with scrambled (top) or AURKA (bottom) shRNA for 30 h, fixed and stained with DAPI
(blue) or ALDH1A1 antibody (red). More than 100 cells were analyzed from multiple random frames. Representative data are shown. g Histogram shows
percentage of BxPC3 cells displaying cytosolic and perinuclear localization in response to AURKA shRNA and (i) MLN8237. Values shown are mean ± SEM
of three independent experiments. * indicate statistically significant differences with respect to controls. p< 0.05 analyzed by two-way analysis of variance.
h AURKA regulates ALDH1A1 subcellular localization using its kinase activity. Unsynchronized cells were treated with either DMSO or MLN8237 for 16 h,
fixed and stained with DAPI or ALDH1A1 antibody. More than 100 cells were analyzed from multiple random frames. Representative data are shown. j, l
AURKA ablation (j) or inhibition (l) results in somewhat perinuclear localization of ALDH1A1 in Panc1 cells. k,m Histogram shows percentage of Panc1 cells
showing cytosolic and perinuclear localization in response to (k) AURKA shRNA and (m) MLN8237. Values shown are mean ± SEM of three
independent experiments. * indicate statistically significant differences with respect to controls. p < 0.05 analyzed by two-way analysis of
variance. Data used to generate the summary statistics shown in panels g, i, k, and m are reported in Additional file 2
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quantification of alterations in AURKA levels upon
ALDH1A1 knock-down from three independent exper-
iments. Similar results were obtained using Panc1 cells,
suggesting that the AURKA-ALDH1A1 feedback activation
loop is a common mechanism in pancreatic cancer cells
(Fig. 4d–g). Data used to generate the summary statistics
shown in Fig. 4c, e, and g are reported in Additional file 4.
We next examined AURKA and ALDH1A1 levels in cyclo-
heximide-treated BxPC3 and ALDH1A1-overexpressing
BxPC3 cells. ALDH1A1 overexpression significantly re-
duced the degradation of AURKA, suggesting that
ALDH1A1 stabilizes AURKA protein levels (Fig. 4h–j).
To further corroborate this finding, we investigated
the ubiquitylation of AURKA in BxPC3 and
ALDH1A1-depleted BxPC3 cells, which showed in-
creased ubiquitylation of AURKA upon ALDH1A1 de-
pletion (Fig. 4k). Together, these results confirm that
ALDH1A1 increases AURKA levels by preventing its deg-
radation, thereby triggering a positive feedback activation
loop.
AURKA phosphorylates ALDH1A1 at T267, T442, and T493
AURKA preferentially phosphorylates the R/K/N-R-X-
S/T-Φ consensus sequence, where Φ denotes a hydro-
phobic residue except for Pro [23]. This preference
suggested T267, T442, and T493 as potential AURKA
sites on ALDH1A1. We generated the corresponding
phosphorylation-resistant mutants, T267A, T442A,
and T493A and analyzed their phosphorylation using
AURKA in vitro. AURKA phosphorylates all the three
sites on ALDH1A1 (Fig. 5a). To investigate whether
AURKA phosphorylates any additional sites, we gener-
ated the corresponding phosphorylation-resistant
triple mutant (T267A, T442A, T493A, denoted as 3A)
and conducted an in vitro kinase assay. AURKA did
not phosphorylate the 3A mutant, confirming that
T267, T442, and T493 are the only AURKA sites on
ALDH1A1 (Fig. 5b).
AURKA regulates the subcellular localization of ALDH1A1
via phosphorylation
To investigate the significance of AURKA-mediated
phosphorylation of ALDH1A1, we initially investigated
the subcellular localization of HA-tagged wild-type
and mutant 3A-ALDH1A1 (T267A, T442A, T493A) in
BxPC3 cells. While wild-type ALDH1A1 displayed
cytoplasmic localization similar to the endogenous en-
zyme, the 3A mutant revealed perinuclear localization,
showing that AURKA-mediated phosphorylation con-
tributes to the cytoplasmic residence of ALDH1A1
(Fig. 5c). We further analyzed total ALDH1A1 (includ-
ing endogenous levels) and ectopically expressed wild-
type and mutant ALDH1A1 in the corresponding cell
lines using ALDH1A1 and HA antibodies, respectively.
While wild-type ALDH1A1-expressing cells showed
diffused cytoplasmic staining of both endogenous and
ectopically expressed ALDH1A1, 3A mutant-expressing
cells showed distinct perinuclear staining of the 3A mu-
tant but cytoplasmic staining for the endogenous enzyme
(Fig. 5d). Together, these results underscore a role of
AURKA in maintaining the cytoplasmic localization of
ALDH1A1.
To investigate the contribution of each of the ALDH1A1
phosphorylation sites in regulating its subcellular localization,
we generated HA-tagged wild-type and phospho-resistant
single mutants of ALDH1A1-expressing BxPC3 cells,
and examined their subcellular localization. Surprisingly,
all single phospho-resistant mutants of ALDH1A1 showed
predominantly cytoplasmic localization, suggesting that
inhibition of phosphorylation at all sites is required for its
perinuclear localization (Fig. 5e).
AURKA increases ALDH1A1 levels via phosphorylation at
all three sites
We next examined the consequences of AURKA-mediated
phosphorylation of ALDH1A1 on its expression levels in
BxPC3 cells. These cells were transfected with wild-type
ALDH1A1 and the 3A-ALDH1A1 allele for 30 h, and their
(See figure on previous page.)
Fig. 2 AURKA binds ALDH1A1 and positively regulates its protein levels. a AURKA and ALDH1A1 associate in BxPC3 cells. AURKA (lane 3) and IgG (lane 1)
were used as positive and negative controls, respectively. b AURKA and ALDH1A1 associate in BxPC3 cells. c, d AURKA and ALDH1A1 associate in Panc1
cells, as shown by reciprocal immunoprecipitation. Each experiment was done at least three independent times. Representative data are shown. e AURKA
overexpression increases ALDH1A1 levels. f AURKA ablation using three different AURKA shRNAs depletes ALDH1A1 in BxPC3 cells. g Histogram shows
relative band intensities normalized to the corresponding tubulin level. Data are expressed as x-fold change relative to control; values shown
as mean ± SEM of three independent experiments. * and # indicate statistically significant differences with respect to controls for AURKA and
ALDH1A1 proteins, respectively. p < 0.05 analyzed by two-way analysis of variance. h AURKA inhibition using MLN8237 (1 μM for 16 h) decreases
ALDH1A1 levels in BxPC3 cells. i AURKA overexpression increases ALDH1A1 levels in Panc1 cells. j Histogram shows relative band intensities
normalized to the corresponding tubulin level. Results are mean ± SEM of three independent experiments. *p < 0.05 vs. AURKA control; #p < 0.05 vs.
ALDH1A1 control analyzed by two-way analysis of variance. k AURKA ablation using three different AURKA shRNAs depletes ALDH1A1 in Panc1 cells. l
Histogram shows relative band intensities normalized to the corresponding tubulin level. Results are mean ± SEM of three independent experiments.
*p < 0.05 vs. AURKA control; #p < 0.05 vs. ALDH1A1 control analyzed by two-way analysis of variance. m AURKA positively regulates ALDH1A1 using its
kinase activity in Panc1 cells. n Histogram shows relative band intensities normalized to the corresponding tubulin level. Data shown are mean ± SEM
of three independent experiments. *p < 0.05 vs. AURKA control; #p < 0.05 vs. ALDH1A1 control analyzed by two-way analysis of variance. Data used to
generate the summary statistics shown in panels g, j, l, and n are reported in Additional file 3
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protein levels analyzed. As shown in Fig. 5f, while wild-type
ALDH1A1 was highly expressed, 3A-ALDH1A1 was
expressed at a much lower level, suggesting that AURKA-
mediated phosphorylation of ALDH1A1 is required to
stabilize its protein levels. Furthermore, as 3A-ALDH1A1
was expressed at a lower level, it led to a concomitant
decrease in the AURKA level, presumably due to the
feedback activation loop.
Our data revealed that AURKA increases ALDH1A1 levels
by inhibiting its ubiquitylation; thus, we examined whether
3A-ALDH1A1 was impervious to AURKA-mediated protein
stability. We transiently depleted AURKA from wild-type
ALDH1A1-BxPC3 and 3A-ALDH1A1-BxPC3 cells and
examined the relative ubiquitylation levels of ALDH1A1.
While wild-type ALDH1A1 was significantly degraded via
ubiquitylation upon AURKA depletion, 3A-ALDH1A1
showed slight ubiquitylation, confirming that AURKA-
mediated phosphorylation is responsible for increased
ALDH1A1 stability (Fig. 5g).
AURKA-mediated stabilization of ALDH1A1 via phos-
phorylation prompted us to analyze potential degron
sites in the ALDH1A1 sequence, which revealed T267
within a D box motif (RVT*L). Although APC-Cdh1-
mediated degradation of D-box-containing proteins can
occur independently of any modification, we hypothesized
that AURKA-mediated stabilization of ALDH1A1 is likely
due to the phosphorylation at T267. Thus, we generated
stably expressing T267A-ALDH1A1-BxPC3 cells. As
controls, we also generated the other two single-mutant
expressing cells (T442A-ALDH1A1-BxPC3 and T493A-
ALDH1A1-BxPC3 cells). ALDH1A1 levels were analyzed
in wild-type, the three single mutant expressing BxPC3
cells, and 3A-BxPC3 cells. As hypothesized, the ALDH1A1
level was reduced in T267A-ALDH1A1-BxPC3 cells com-
pared to wild-type ALDH1A1-expressing cells; however,
interestingly, it was also reduced in T442A-ALDH1A1-
BxPC3 and T493A-ALDH1A1-BxPC3 cells, with the triple
mutant showing minimal protein levels, suggesting that
phosphorylation of each of the three sites contributes to in-
creased ALDH1A1 levels (Fig. 5h and i).
As our data showed that AURKA increases ALDH1A1
levels by inhibiting its ubiquitylation, we analyzed the contri-
bution of each of these three sites in affecting protein stabil-
ity. The mutant ALDH1A1-expressing cell lines displayed a
similar steady state decrease in ALDH1A1 levels compared
to wild-type ALDH1A1-expressing cells, as shown in Fig. 5h
and i. We then transiently knocked down AURKA in these
cells using AURKA shRNA, which resulted in robust
ubiquitylation of wild-type ALDH1A1, followed by each
of the three single mutants with relatively less ubiquityla-
tion (Fig. 5j). The 3A-ALDH1A1 mutant displayed minimal
ubiquitylation upon AURKA depletion, confirming its inde-
pendence from AURKA-mediated phosphorylation. These
results demonstrate that AURKA-mediated phosphoryl-
ation of ALDH1A1 at each of the three sites (T267, T442,
and T493) contributes to increased protein stability.
AURKA increases ALDH1A1 activity predominantly via
phosphorylation at the T267 site
ALDH1A1 has an NAD+ binding pocket (from amino
acids 8–135 and 159–270), a catalytic site (271–470) and
an oligomerization domain (amino acids 140–158 and
486–495). T267 is within the NAD+ binding pocket
(Fig. 6a). The neighboring E269 residue in the active site
is essential for catalysis, suggesting that phosphorylation
at T267 may have a direct impact on the catalytic activ-
ity of ALDH1A1. T442 is within the catalytic domain
and T493 is part of the oligomerization domain, which is
involved in oligomer formation (Fig. 6a). Thus, we hypothe-
sized that all the three phosphorylation sites may partici-
pate in regulating ALDH1A1 enzymatic activity. Although
all single mutants exhibited a robust decrease in activity
relative to the wild-type enzyme, the T267 mutant showed
no activity, suggesting that phosphorylation at T267 pri-
marily governs ALDH1A1 activity (Fig. 6b).
AURKA-mediated phosphorylation of ALDH1A1 regulates
its oligomeric states
ALDH1A1 can exist in monomeric, dimeric or tetrameric
forms; however, their relative activities remain unknown.
(See figure on previous page.)
Fig. 3 AURKA stabilizes ALDH1A1 protein levels and increases its enzymatic activity. a AURKA prevents ALDH1A1 degradation. AURKA-BxPC3 and
BxPC3 cells were treated with cycloheximide for 2 and 4 h, and AURKA and ALDH1A1 levels analyzed. b Graphical representation of AURKA degradation
rate. The results of densitometric scanning are shown graphically with AURKA signal normalized to actin signal. AURKA half-life is ~2 h. The significance of
the difference between means was determined by Duncan’s multiple range test, *p < 0.05. c Graphical representation of ALDH1A1 degradation
rate. ALDH1A1 half-life is ~2 h, *p < 0.05. d AURKA stabilizes ALDH1A1 by inhibiting its ubiquitylation. Each experiment was done at least three
independent times. Representative data are shown. e, f AURKA increases ALDH1A1 enzymatic activity. Comparative spectrophotometric ana-
lysis of ALDH1A1 activity upon phosphorylation by AURKA. ALDH1A1 activity with and without ATP and AURKA were used as controls. The in-
crease in ALDH1A1 activity observed in the presence of ATP can be overcome by stringent purification of ALDH1A1 (compare e and f). g
Stoichiometry of ALDH1A1 phosphorylation by AURKA after 1.5 and 6 h. h, i Coupling the change in ALDH1A1 activity with stoichiometry of
ALDH1A1 phosphorylation. Two identical reaction mixtures were treated with cold ATP to measure ALDH1A1 activity (h, i), or with cold ATP spiked with
0.01 μCi of [32P]ATP (g). After 1.5 and 6 h kinase reactions, 32P incorporation (g) and ALDH1A1 activity (h, i) were measured. j Dephosphorylation
of ALDH1A1 by calf-intestinal alkaline phosphatase (CIP) decreases its dehydrogenase activity. Each experiment was done at least three
independent times. Representative data are shown
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As phosphorylation is known to regulate the oligomeric
distribution of several proteins, we hypothesized that
AURKA-mediated phosphorylation of ALDH1A1 alters
its oligomeric state, and that this change was coupled
with the observed change in activity. Similar to most
multimeric proteins, ALDH1A1 exists predominantly
as a tetramer at high concentrations; however, as the dilu-
tion increases, the equilibrium becomes more dynamic
and begins to populate the monomeric form. Surprisingly,
very little dimer was observed at all concentrations, sug-
gesting that the tetramer and the monomer are its most
abundant forms.
We monitored the abundance of each species upon
phosphorylation as a function of time to analyze the
kinetics of the phosphorylation-dependent oligomeric
redistribution of ALDH1A1. To this end, we chose a
a
e f
h i j k
g
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Fig. 4 ALDH1A1 positively regulates AURKA protein levels by preventing its degradation. a ALDH1A1 overexpression increases AURKA levels.
Wild-type HA-tagged ALDH1A1-BxPC3 cells were generated by infecting the corresponding retrovirus. b ALDH1A1 knock-down using two
different ALDH1A1 shRNAs depletes AURKA in BxPC3 cells. Cells were transfected with scrambled shRNA (lane 1), ALDH1A1-shRNA1 or 2
(lanes 2 and 3, respectively), and AURKA and ALDH1A1 levels were analyzed after 30 h. c Histogram shows relative band intensities normalized to the
corresponding tubulin level. Data shown are mean ± SEM of three independent experiments. * and # indicate statistically significant differences with
respect to controls for ALDH1A1 and AURKA proteins, respectively. p < 0.05 analyzed by two-way analysis of variance. d ALDH1A1 overexpression
increases AURKA levels in Panc1 cells. e Histogram shows relative band intensities normalized to the corresponding tubulin level. Data shown
as mean ± SEM of three independent experiments. * and # indicate statistically significant differences with respect to controls for ALDH1A1 and
AURKA proteins, respectively. p < 0.05 analyzed by two-way analysis of variance. f ALDH1A1 depletion decreases AURKA levels in Panc1 cells. g
Histogram shows relative band intensities normalized to the corresponding tubulin level. Data shown as mean ± SEM of three independent
experiments. h ALDH1A1 inhibits AURKA degradation. i Graphical representation of ALDH1A1 degradation rate. The significance of the difference between
means was determined by Duncan’s multiple range test, *p< 0.05. j Graphical representation of AURKA degradation rate, *p< 0.05. k ALDH1A1 stabilizes
AURKA by inhibiting its ubiquitylation. Each experiment was done at least three independent times. Representative data are shown. Data used to generate
the summary statistics shown in panels c, e, and g are reported in Additional file 4
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concentration which contained both tetrameric and
monomeric species. As the phosphorylation progressed, the
ALDH1A1 oligomeric distribution drastically shifted to the
monomeric form (Fig. 6c). The concomitant decrease in
tetramer abundance serves as an internal control to validate
that it is indeed dissociating upon phosphorylation. While
Fig. 6d shows average relative changes in tetramer and
monomer abundance, Fig. 6e displays the average ratio of
normalized monomer to tetramer as a function of time de-
rived from three independent experiments.
We then sought to explore which oligomeric species
had the highest activity with and without phosphorylation.
To this end, we conducted a similar kinetic analysis and
measured the dehydrogenase activity using a native in-gel
activity assay (Fig. 6f, g). Upon phosphorylation the mono-
meric species that formed harbored the highest activity
(a greater than sevenfold increase), whereas the tetramer
showed little to no change. Figure 6h shows quantification
of oligomer-specific ALDH1A1 activities from three inde-
pendent experiments. This is the first example to identify
the oligomer-specific catalytic activities of ALDH1A1 com-
plexes following phosphorylation.
We next sought the oligomeric species that was most
phosphorylated to examine a potential correlation between
phosphorylation and activity. As predicted, the monomeric
population that formed was highly phosphorylated
(Fig. 6i–k). Collectively, these data suggest that phosphoryl-
ation of ALDH1A1 triggers the dissociation of the tetramer
into its monomeric form and that this highly phosphory-
lated monomer harbors the highest enzymatic activity
among all of the oligomeric species. Data used to generate
the summary statistics shown in Fig. 6d, e, h, and k are re-
ported in Additional file 5.
ALDH1A1 and AURKA feedback activation loop promotes
highly aggressive pancreatic cancer phenotypes
Since AURKA is crucial for mitosis, we examined whether
ALDH1A1 impacts the cell cycle. A fluorescence-
activated cell sorting (FACS) analysis was conducted
using unsynchronized stable scrambled shRNA-expressing
BxPC3 and stable ALDH1A1-depleted BxPC3 cells. Both
cell types showed a similar distribution of cells in different
cell cycle phases and no aneuploidy, which suggests that
ALDH1A1 does not affect the cell cycle (Fig. 7a). We next
investigated the effect of AURKA-mediated phosphoryl-
ation of ALDH1A1 on cellular proliferation. As expected,
ectopic expression of either AURKA or wild-type
ALDH1A1 increased cellular proliferation in both BxPC3
(Fig. 7b) and Panc1 cells (Fig. 7c). In contrast, expression
of 3A-ALDH1A1 showed a significantly impaired pro-
liferation rate, which was lower than either BxPC3
(Fig. 7b) or Panc1 cells (Fig. 7c). More importantly, deple-
tion of AURKA in BxPC3, ALDH1A1-BxPC3, and 3A-
ALDH1A1-BxPC3 cells significantly reduced prolifera-
tion in ALDH1A1-BxPC3 cells but not in 3A-
ALDH1A1-BxPC3 cells, suggesting that the
ALDH1A1-triggered increase in cell proliferation is
predominantly due to an AURKA-mediated feedback
activation loop (Fig. 7d). We further tested this hy-
pothesis by overexpressing AURKA in BxPC3,
ALDH1A1-BxPC3, and 3A-ALDH1A1-BxPC3 cells. In
agreement with our previous result, AURKA overexpres-
sion increased cell proliferation in wild-type ALDH1A1-
BxPC3 cells, but not in 3A-ALDH1A1-BxPC3, thereby
confirming that AURKA-mediated phosphorylation of
ALDH1A1 is crucial for an enhanced growth rate
(Fig. 7e). Similar results were obtained in Panc1 cells,
where AURKA depletion significantly reduced prolifera-
tion in ALDH1A1-BxPC3 cells, but not in 3A-ALDH1A1-
BxPC3 cells (Fig. 7f), whereas the AURKA overexpression
mediated increase in cell proliferation in wild-type
ALDH1A1-Panc1 cells, but not in 3A-ALDH1A1-Panc1
cells (Fig. 7g).
The impact of ALDH1A1 was further evaluated in
BxPC3, ALDH1A1-BxPC3 and 3A-ALDH1A1-BxPC3
cells under anchorage-independent conditions. ALDH1A1
(See figure on previous page.)
Fig. 5 AURKA-mediated phosphorylation of ALDH1A1 at T267, T442, and T493 regulates its protein stability and subcellular localization. a AURKA
phosphorylates ALDH1A1 at T267, T442, and T493. Phospho-dead single mutants of ALDH1A1 were subjected to an in vitro kinase assay using
AURKA/TPX2 and [32P]ATP. b T267, T442, and T493 are the only AURKA sites on ALDH1A1, as the 3A-ALDH1A1 mutant is not phosphorylated by
AURKA. c AURKA regulates the subcellular localization of ALDH1A1 via phosphorylation. HA-tagged wild-type and 3A-ALDH1A1-expressing stable
cells were fixed and immunostained with DAPI (blue) and antibody against HA (green). More than 100 cells were analyzed from multiple random
frames. Representative data are shown. d Double staining of total ALDH1A1 and ectopically expressed ALDH1A1 in wild-type and 3A-expressing
BxPC3 cells. e AURKA regulates the subcellular localization of ALDH1A1 via phosphorylation of all three sites. More than 100 cells were analyzed
from multiple random frames. Representative data are shown. f AURKA promotes ALDH1A1 levels by phosphorylation. BxPC3 cells were infected
with HA-tagged wild-type ALDH1A1 or 3A-ALDH1A1 retrovirus. After 30 h, protein levels were analyzed using AURKA, HA, and actin antibodies. g
AURKA inhibits ALDH1A1 ubiquitylation by phosphorylating T267, T442, and T493. h AURKA increases ALDH1A1 levels by phosphorylation at
T267, T442, and T493. i Graphical representation of ALDH1A1 levels in BxPC3 cells expressing either wild-type or mutant ALDH1A1. Average values
of wild-type and mutant ALDH1A1 levels from three independent experiments are depicted in the graph. **p < 0.01, compared to control
analyzed by two-way analysis of variance. j AURKA inhibits ALDH1A1 ubiquitylation by phosphorylating T267, T442, and T493 sites. BxPC3 cells
expressing either wild-type ALDH1A1, T267A-ALDH1A1, T442A-ALDH1A1, T493A-ALDH1A1, or 3A-ALDH1A1 were co-infected with AURKA shRNA
along with 6x-His-ubiquitin. Ubiquitylated proteins were isolated and analyzed as described in Methods. Each experiment was done at least three
independent times. Representative data are shown
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expression led to a robust increase in colony formation in
BxPC3 cells compared to parental BxPC3 cells. By contrast,
expression of 3A-ALDH1A1 acted as dominant negative
and exhibited minimal number of colonies in the soft agar
assay (Fig. 7h). Similar results were also obtained in Panc1
cells (Fig. 7i). These findings show that AURKA-mediated
phosphorylation of ALDH1A1 is crucial for promoting
cell proliferation both under attached and anchorage-
independent conditions in pancreatic cancer cells.
ALDH1A1 and AURKA feedback activation loop enhances
cell motility
We next determined the contribution of ALDH1A1 in
promoting chemotaxis using serum-starved BxPC3,
ALDH1A1-BxPC3, and 3A-ALDH1A1-BxPC3 cells. A
robust increase in cell motility was observed upon
wild-type ALDH1A1 expression (Fig. 7j). However, ex-
pression of 3A-ALDH1A1 significantly impaired cell
motility compared to vector-expressing BxPC3 cells,
suggesting that 3A-ALDH1A1 may act as a dominant
negative and inhibit cell motility. To further explore
the impact of AURKA on ALDH1A1-mediated motil-
ity, we depleted AURKA in BxPC3, ALDH1A1-BxPC3,
and 3A-ALDH1A1-BxPC3 cells, which considerably
reduced cell motility in ALDH1A1-BxPC3 cells, but
not in 3A-ALDH1A1-BxPC3 cells, suggesting that the
ALDH1A1-triggered increase in cell motility is due to
AURKA-mediated positive regulation (Fig. 7k). We
further tested this hypothesis by overexpressing AURKA
in BxPC3, ALDH1A1-BxPC3, and 3A-ALDH1A1-BxPC3
cells. AURKA overexpression increased cell migration in
wild-type ALDH1A1-BxPC3 cells, but not in 3A-
ALDH1A1-BxPC3 cells (Fig. 7l). This result was further
validated in Panc1 cells, where wild-type ALDH1A1 ex-
pression showed a drastic increase in cell motility while
3A-ALDH1A1 showed significant inhibition when
compared to wild-type Panc1 cells (Fig. 7m, n). Simi-
larly, AURKA depletion significantly reduced cell motil-
ity in ALDH1A1-BxPC3 cells, but not in 3A-
ALDH1A1-BxPC3 cells (Fig. 7o, p), while AURKA over-
expression increased cell migration in wild-type
ALDH1A1-Panc1 cells, but not in 3A-ALDH1A1-Panc1
cells (Fig. 7q, r). Data used to generate the summary
statistics shown in Fig. 7c, f, g, i, n, p, and r are reported
in Additional file 6. Together, these results corroborate that
AURKA-mediated phosphorylation of ALDH1A1 plays a
key role in increasing cell motility. As chemotaxis plays a
key role in cancer metastasis, these results underscore a
crucial oncogenic role of the AURKA-ALDH1A1 feedback
activation loop in pancreatic malignancy.
ALDH1A1 upregulation is a key mechanism by which
AURKA increases EMT and CSC phenotypes
A pivotal role of ALDH1A1 in inducing EMT and CSC
is well delineated. A recent study has also reported that
AURKA leads to EMT using MLN8237; however, the
mechanism remains unclear [24]. Our data suggest that
ALDH1A1 upregulation may be a key mechanism by
which AURKA leads to EMT and CSC. Thus, to test this
hypothesis, we examined potential modulation of E-
cadherin, Snail, Slug, and CD44p using corresponding lucif-
erase plasmids which measure their promoter activities. As
shown in Fig. 8a, expression of wild-type ALDH1A1 led to
a robust increase in the activities of Snail, Slug, and CD44p,
but had minimal effect on E-cadherin activity. More
importantly, ectopic expression of the phosphorylation-
resistant triple mutant not only prevented the increase
in promoter activities of CD44, Slug, and Snail, but in
effect resulted in even less activity compared to parental
cells, thereby underscoring a crucial role of AURKA in
ALDH1A1-induced aggressive oncogenic phenotypes.
(See figure on previous page.)
Fig. 6 AURKA-mediated phosphorylation of ALDH1A1 modulates its oligomeric state and dehydrogenase activity. a Monomeric ALDH1A1 and
three AURKA phosphorylation sites (4WB9). T267 is within the NAD+ binding pocket, T442 is within the catalytic site, and T493 is within the oligomerization
domain. b ALDH1A1-phosphorylation-resistant mutants have diminished enzymatic activity. c Phosphorylation of ALDH1A1 by AURKA triggers ALDH1A1
oligomers to dissociate to the monomeric form. The same membrane is shown as a short (top) and long (bottom) exposure for clarity. d Average relative
changes in tetramer and monomer abundance derived from three independent experiments. The intensities of tetramer and monomer at each time were
normalized independently against time 0. Quantification of tetramer and monomer intensities was derived from the short exposure (**p< 0.01 monomer at
0 and 30 min) from three independent experiments. e Average ratio of normalized monomer to tetramer as a function of time. To account for the large
difference in tetramer and monomer abundance, the intensity of each band was normalized against the tetramer intensity at time zero and the ratio of
monomer to tetramer was plotted as a function of time. After 30 min, a significant increase in the monomer to tetramer was observed (***p< 0.01 at 0
and 30 min). f Activity staining of phosphorylation-induced ALDH1A1 monomer harbors high dehydrogenase activity. Purple color is used to denote it as
activity-based staining. g Coomassie G-250 stain of panel f. h Quantification of oligomer-specific ALDH1A1 activities from three independent experiments
(***p< 0.001 at 0 and 30 min) analyzed by two-way analysis of variance. Specifically, monomer and tetramer intensities of activity and Coomassie stain at
30 min of phosphorylation were normalized against the unphosphorylated tetramer control (basal activity), then the normalized activity of each oligomer
was divided by its respective normalized Coomassie signal to generate the plot shown. i Phos-tag staining of phosphorylated ALDH1A1. j Coomassie
G-250 stain of panel i. k Quantification of normalized Phos-tag intensities with respect to total protein levels from three independent experiments. Protein
quantification was carried out in the same way as described for the activity assay (***p< 0.001 for monomer at 0 and 10 min and 0 and 30 min analyzed
by two-way analysis of variance). The red color denotes it as a phosphorylation-specific signal. Data used to generate the summary statistics shown in
panels d, e, h, and k are reported in Additional file 5
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To further confirm these results, we analyzed the protein
levels of N-cadherin, CD44, Slug, Snail, and E-cadherin in
BxPC3, wild-type ALDH1A1-BxPC3, and 3A-ALDH1A1-
BxPC3 cells. E-cadherin is an epithelial cell marker, which is
downregulated upon EMT, while Snail, Slug, and CD44p are
increased in cells undergoing EMT and CSC. Similar to the
promoter activation assays, N-cadherin, CD44, Slug, and
Snail levels increased considerably upon ALDH1A1 expres-
sion, but were prevented in the presence of 3A-ALDH1A1
in BxPC3 cells, confirming that the phosphorylation-
resistant mutant serves as a dominant negative (Fig. 8b).
In addition, E-cadherin levels decreased in ALDH1A1-
overexpressing cells, but showed a significant increase
in 3A-ALDH1A1 cells. We also analyzed the levels of
vimentin and matrix metalloproteinase-2 (MMP-2), levels
of which are known to increase in EMT-undergoing cells
and promote tumor invasion. ALDH1A1 overexpression
increased both vimentin and MMP-2 levels in BxPC3
cells, whereas phospho-resistant mutant expression abol-
ished their expression. Collectively, these results validate
that AURKA-mediated phosphorylation plays a key role in
ALDH1A1-mediated aggressive phenotypes.
In parallel, we also analyzed the levels of E-cadherin,
N-cadherin, CD44, vimentin, MMP-2, Slug, and Snail in
BxPC3 cells treated either with DMSO control or
MLN8237. AURKA inhibition reduced the levels of N-
cadherin, CD44, vimentin, MMP-2, Slug, and Snail, but
increased E-cadherin levels in pancreatic cancer cell
lines (Fig. 8c). These findings further underscored a key
role of AURKA in promoting EMT in pancreatic cancer,
presumably by modulating ALDH1A1 levels and activity.
We next conducted a sphere-forming assay to gauge
the self-renewal capacity of BxPC3, ALDH1A1-BxPC3,
and 3A-ALDH1A1-BxPC3 cells using ultralow attach-
ment conditions. Under these conditions, cancer stem
cells grow in suspension and form independent spheres
or colonies. As shown in Fig. 8d, parental BxPC3 mainly
formed aggregates of cells with no pancreatosphere
formation. In contrast, overexpression of ALDH1A1
induced large pancreatosphere formation, confirming
that ALDH1A1 overexpression causes the CSC pheno-
type. Importantly, 3A-ALDH1A1-BxPC3 cells also showed
no pancreatosphere formation, thereby confirming that
AURKA-mediated phosphorylation of ALDH1A1 is
crucial for inducing the CSC phenotype.
ALDH1A1 phosphorylation contributes to drug resistance
As both EMT and CSC contribute to drug resistance, we
examined doxorubicin sensitivity in BxPC3 cells, which
revealed about 50% loss in cell viability in 72 h at 1 μM
concentration (Fig. 8e). Expression of wild-type ALDH1A1
in BxPC3 rendered these cells significantly resistant to
doxorubicin (~30% loss in cell viability in 72 h), whereas
3A-ALDH1A1 expression conferred high sensitivity to
doxorubicin-induced toxicity (~70% loss in cell viability)
(Fig. 8e). These findings suggest that AURKA-mediated
phosphorylation of ALDH1A1 considerably contributes to
the drug resistance observed in patients with pancreatic
ductal adenocarcinoma (PDAC). These results led us to
investigate whether ablation of AURKA sensitizes BxPC3
cells to ALDH1A1 inhibition. We used N,N-diethylamino-
benzaldehyde (DEAB) to inhibit ALDH1A1, although it is
not very selective and inhibits other ALDH isozymes as
well. As shown in Fig. 8f, AURKA-depleted cells exhibit
higher sensitivity to ALDH1A1 inhibition compared to
scrambled shRNA-expressing cells, suggesting that tar-
geting the AURKA-ALDH1A1 axis is likely to be more
effective than individually targeting either AURKA or
ALDH1A1.
(See figure on previous page.)
Fig. 7 ALDH1A1 is a key oncogenic effector of AURKA. a scrambled shRNA-expressing BxPC3 and ALDH1A1 knock-down-BxPC3 cells were
analyzed by FACS analysis. b ALDH1A1 promotes cell proliferation in BxPC3 cells. BxPC3, AURKA-BxPC3, ALDH1A1-BxPC3, and 3A-ALDH1A1-BxPC3
cells were plated in 96-well plates and cultured for 24, 48, and 72 h. At the end of the incubation, an MTT assay was performed. c ALDH1A1
promotes cell proliferation in Panc1 cells. d AURKA depletion decreases cell proliferation in ALDH1A1-BxPC3 cells, but not in phospho-resistant
3A-ALDH1A1-BxPC3 cells. MTT assay was performed after 48 h of transfection. The statistical significance was analyzed using two-independent-sample
t test, *p < 0.05, **p < 0.01 compared to scrambled shRNA controls. e AURKA overexpression increases cell proliferation in ALDH1A1-BxPC3 cells, but
not in 3A-ALDH1A1-BxPC3 cells. MTT was performed after 48 h of transfection. *p < 0.05 compared to vector-infected controls analyzed using
two-independent-sample t test. f AURKA depletion decreases cell proliferation in ALDH1A1-Panc1 cells, but not in phospho-resistant
3A-ALDH1A1-Panc1 cells. g AURKA overexpression increases cell proliferation in ALDH1A1-Panc1 cells, but not in 3A-ALDH1A1-Panc1 cells. h, i
ALDH1A1 promotes colony formation in a soft agar assay in (h) BxPC3 and (i) Panc1 cells. *p < 0.05 compared to vector-expressing control analyzed by
two-way analysis of variance. j ALDH1A1 promotes cell motility in BxPC3 cells. **p < 0.01 compared to vector-expressing control by two-tailed Student’s
t test. k AURKA depletion inhibits cell motility in ALDH1A1-BxPC3 cells, but not in phospho-resistant 3A-ALDH1A1-BxPC3 cells. **p < 0.01 compared to
scrambled shRNA control by two-tailed Student’s t test. l AURKA overexpression increases cell motility in ALDH1A1-BxPC3 cells, but not in 3A-
ALDH1A1-BxPC3 cells. m ALDH1A1 promotes cell motility in Panc1 cells. Chemotaxis assay was performed in ALDH1A1-Panc1 and 3A-ALDH1A1-Panc1
using Boyden chambers. These experiments were performed three independent times. Representative data are shown. Magnification, 200×. n
Histogram shows mean ± SEM of three independent experiments. **p < 0.01 compared to vector-expressing control analyzed by two-way analysis
of variance. o, p AURKA depletion inhibits cell motility in ALDH1A1-Panc1 cells, but not in phospho-resistant 3A-ALDH1A1-Panc1 cells. q, r AURKA
overexpression increases cell motility in ALDH1A1-Panc1 cells, but not in 3A-ALDH1A1-Panc1 cells. Data used to generate the summary statistics
shown in panels c, f, g, i, n, p, and r are reported in Additional file 6
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To test this hypothesis, we treated BxPC3 cells with
100 μM DEAB for 24 h, which showed minimal toxicity,
suggesting inhibition of ALDH1A1 alone does not confer
toxicity to cells (Fig. 8g, h, bar graph and line graph,
respectively). In contrast, AURKA inhibition showed ~32%
and ~35% loss in cell viability at 1 and 1.5 μM MLN8237
concentrations, respectively. More importantly, co-
inhibition of ALDH1A1 and AURKA was highly
effective, particularly, at 1.5 μM MLN8237 concentration,
which showed more than 65% loss in cell viability. These
findings underscore the significance of the AURKA-
ALDH1A1 feedback activation loop in pancreatic carcin-
oma and suggest that concurrent inhibition of AURKA
and ALDH1A1 is likely to be highly effective in targeting
highly chemoresistant PDAC (Fig. 8i).
Discussion
ALDH1A1 is a cytosolic enzyme which catalyzes the
oxidation of various aldehydes including trans- and cis-
retinal to their corresponding less reactive acids, thereby
aiding the cell in detoxifying these compounds. ALDH1A1
also binds to endobiotics and xenobiotics and possesses
antioxidant activity [25, 26]. ALDH1A1 is highly expressed
in normal stem cells, but is also widely used as a marker
to identify and isolate various types of CSCs. ALDH1A1
level and activity are upregulated in patients treated with
neoadjuvant chemotherapy and are associated with ex-
treme chemoresistance and poor prognosis in pancre-
atic cancer and beyond. Thus, there is a critical need to
develop therapies that target ALDH1A1 alone or in
combination to eliminate these “stem cell-like” tumor
cells in pancreatic and other types of cancer.
While several studies have shown increased mRNA or
protein levels of ALDH1A1 in different cancers, the
molecular mechanism remains unclear. There is no re-
port that shows phosphorylation-dependent regulation
of ALDH1A1 to date. We show that AURKA directly
phosphorylates ALDH1A1 at T267, T442, and T493,
which stabilizes ALDH1A1. ALDH1A1 also stabilizes
AURKA levels by inhibiting its ubiquitylation, thereby
triggering a reciprocal feedback activation loop. Inter-
estingly, each of the three sites contributes towards
ALDH1A1 stability. Furthermore, ectopic expression of
phospho-resistant ALDH1A1 prevents the promoter
activation of Slug, Snail, CD44, and N-cadherin while
simultaneously failing to repress E-cadherin promoter,
suggesting that inhibition of AURKA-mediated phosphoryl-
ation impairs its transcriptional activity. Importantly, ec-
topic expression of phospho-resistant ALDH1A1 not only
fully inhibits ALDH1A1-mediated oncogenic pathways, but
even reduces the basal levels of Snail, Slug, N-cadherin,
vimentin, MMP-2, and CD44 in BxPC3 cells, highlighting a
vital role of AURKA in ALDH1A1-mediated signaling in
cancer cells.
We also show that AURKA-mediated phosphorylation
at the T267 site increases ALDH1A1 activity. Recent global
phospho-proteomics analysis studies indeed observed
increased phosphorylation at the T267 site on ALDH1A1
in human colorectal cancer and non-small lung cancer
tissues [27, 28]; however, the kinase responsible remains
unknown. Similarly, Han et al. reported increased phos-
phorylation at T267 on ALDH1A1 in human liver tissues
[29]. ALDH1A1 is highly expressed in the liver and is
crucial for the prevention of dietary retinol-induced
liver toxicity [30], suggesting that AURKA-mediated in-
crease in ALDH1A1 levels and activity may also be essential
for normal tissues which require high ALDH1A1 activity.
Thus, these studies not only underscore the clinical sig-
nificance of AURKA-mediated regulation of ALDH1A1
in several cancers, but also highlight that the AURKA-
ALDH1A1 axis may have an important role in normal
tissue homeostasis.
Furthermore, our study showed that AURKA phos-
phorylates ALDH1A1 at T493, which is located within
(See figure on previous page.)
Fig. 8 AURKA-mediated phosphorylation of ALDH1A1 is crucial for ALDH1A1-induced EMT, CSC, and drug resistance. a ALDH1A1 expression
increases CD44, Slug, and Snail promoter activities, whereas 3A-ALDH1A1 expression decreases CD44, Slug, and Snail promoter activities.
BxPC3, ALDH1A1-BxPC3, and 3A-ALDH1A1-BxPC3 cells were plated in 96-well plates overnight and then transfected with CD44, Slug, Snail,
and E-cadherin promoter-driven luciferase plasmids as described in Methods. After 48 h, luciferase activities were measured with the Dual
Luciferase kit (Thermo Fisher Scientific). All experiments were done in triplicate, three independent times. *p < 0.05 and **p < 0.01, compared
to control BxPC3 cells analyzed by two-way analysis of variance. b ALDH1A1 expression increases the levels of EMT and CSC markers while
decreasing E-cadherin levels, whereas 3A-ALDH1A1 expression decreases the levels of EMT and CSC markers while increasing E-cadherin levels.
c AURKA inhibition using MLN8237 decreases the levels of EMT and CSC markers, but increases E-cadherin levels. d ALDH1A1 overexpression
increases sphere-forming ability in BxPC3 cells. BxPC3, ALDH1A1-BxPC3, and 3A-ALDH1A1-BxPC3 cells were incubated in ultralow attachment
plates as described in Methods. Pancreatospheres were counted after 5 days. e ALDH1A1 overexpression increases drug resistance in BxPC3
cells. BxPC3, wild-type ALDH1A1-BxPC3, and 3A-ALDH1A1-BxPC3 cells were plated in 96-well plates overnight, doxorubicin (1 μM) was added,
and cells cultured for another 24, 48, or 72 h. Cell viability was calculated by MTT assay. f AURKA ablation sensitizes BxPC3 cells to ALDH1A1
inhibition using N,N-diethylaminobenzaldehyde (DEAB). BxPC3 cells were either incubated with DEAB (100 μM) or with vehicle (DMSO). After
48 h, cell viability was analyzed. *p < 0.05 and **p < 0.01 compared to scrambled shRNA control by two-tailed Student’s t test. g ALDH1A1
inhibition sensitizes BxPC3 cells to AURKA inhibition. BxPC3 cells were treated with 100 μM DEAB and varying concentrations of MLN8237
(0–3 μM) for 24 h and cell viability analyzed. h Same data as in g but shown as line graph. i Proposed model showing AURKA-ALDH1A1 axis
in promoting EMT, CSC, and chemoresistance in pancreatic cancer
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its oligomerization domain. ALDH1A1 exists as a tetra-
mer, which is a dimer of a dimer (A-B + C-D). However,
the relative enzymatic activities of its monomeric, dimeric,
and tetrameric forms still remain unclear. One study
reported that heating of ALDH1A1 increases the con-
version of the dimeric form to the monomeric form,
which is associated with decreased activity, although
this study did not analyze the activity of the tetrameric
form of ALDH1A1 [31]. Class II ALDH enzymes, such
as ALDH2, display half-of-the-sites reactivity in tetra-
meric form, which can assume full reactivity depending
on the pH or in the presence of divalent cations. Ac-
cordingly, increasing the Mg2+ concentration from 0 to
0.4 mM resulted in a two-fold increase in horse liver
ALDH2 activity which was accompanied by the dissoci-
ation of tetrameric enzyme into dimers [32]. Similarly,
with increasing pH, the tetrameric ALDH2 enzyme dis-
sociated to the more active dimeric state even in the
absence of Mg2+ ions [33]. These findings suggest that
Class II ALDHs display higher activity in the dimeric
state; however, it is not known whether ALDH1A1
(which belongs to Class I) displays similar kinetics in
the dimeric and tetrameric states. Furthermore, the ac-
tivity of a Class I ALDH such as ALDH1A1 is inhibited
in the presence of Mg2+, suggesting that Class I and
Class II ALDHs are regulated differently. To date, no
study has investigated phosphorylation as a potential
mechanism which governs these reported changes in
ALDH1A1’s oligomeric state and enzymatic activity.
Our data show that AURKA-mediated phosphorylation
of ALDH1A1 shifts the total population to its monomeric
form, which harbors higher dehydrogenase activity relative
to the tetramer. Surprisingly, unlike Class II ALDH, we
did not observe substantial dimeric species in either the
unphosphorylated or phosphorylated state. It is likely that
in cells, the monomeric phosphorylated form may be re-
incorporated into high order oligomers to form the active
tetramer when ALDH1A1 levels are high. Alternatively,
the cells may keep ALDH1A1 activity in check by storing
excess enzyme in the less active tetrameric form, which is
capable of readily dissociating to form the highly active
phospho-monomer for rapid temporal response. While
future studies are needed to uncover this mechanism, the
phospho-oligomeric regulation of ALDH1A1 could be
exploited as a novel therapeutic intervention.
Conclusions
In conclusion, we unraveled a novel mechanism of
ALDH1A1 regulation that is triggered by AURKA.
While extreme chemoresistance and CSC formation
are the defining features of pancreatic cancer, the
mechanism by which AURKA may be involved in these
processes has not been examined. Our discovery of
ALDH1A1 as an AURKA substrate provides a novel
mechanism by which AURKA promotes chemoresistance
and stem cell formation in pancreatic cancer via ALDH1A1
and vice versa. Thus, targeting AURKA and ALDH1A1
in combination is expected to be highly effective in
inhibiting tumorigenesis, chemoresistance, and metas-
tasis in highly lethal pancreatic carcinoma. Further-
more, analysis of ALDH1A1 phosphorylation levels
should aid in the development of diagnostic and prog-
nostic biomarkers for identifying patients with suitable
molecular phenotypes for maximal therapeutic benefit,
avoiding treatment of unresponsive patients and im-
proving overall quality of life.
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